Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com


  • Pretty weak financial results growth rate 7.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (15.3%)
  • Dividend yield for the last twelve months 6.2%
  • Free cash flow yield -3.9% (LTM)
  • Share price is 29.4% higher than minimum and 17.7% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.9x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders bought company shares on $2.9 mln (0.002% of cap.)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (+0.7%)27.93
year average price 26.05  


year start price 24.09 2025-09-24

min close price 23.60 2025-09-25

max close price 29.02 2026-09-02

current price 27.93 2026-09-23
Common stocks: 5 615 000 000

Dividend Yield:  6.2%
FCF Yield LTM: -3.9%
EV / LTM EBITDA: 9.9x
EV / EBITDA annualized: 10.0x
Last revenue growth (y/y):  +2.6%
Last growth of EBITDA (y/y):  +11.5%
Historical revenue growth:  +8.7%
Historical growth of EBITDA:  +22.0%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 156 827
Net Debt ($m): 54 937
EV (Enterprise Value): 211 764
EBITDA LTM ($m): 21 496
EV / LTM EBITDA: 9.9x
Price to Book: 1.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-08seekingalpha.com

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

2026-02-06cnbc.com

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

2026-02-06zacks.com

Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push

2026-02-06businesswire.com

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

2026-02-05businesswire.com

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

2026-02-04proactiveinvestors.co.uk

Novo Nordisk: Pfizer weight loss drug offers credible new competition

2026-02-03fool.com

Will the Market Crash in 2026? Here's What History Says and What to Do About It

2026-02-03fool.com

Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off

2026-02-03seekingalpha.com

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

2026-02-03benzinga.com

Silver Surges Over 15%; Pfizer Earnings Top Views
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data